These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 1791327)
1. [Spheroplast formation in clinical isolates of gram-negative bacteria by beta-lactam antibiotic in the presence of Ca2+ or Mg2+]. Tada Y; Yamaguchi J Kansenshogaku Zasshi; 1991 Oct; 65(10):1304-8. PubMed ID: 1791327 [TBL] [Abstract][Full Text] [Related]
2. Spheroplast induction in clinical isolates of Serratia marcescens in the presence of Ca2+ or Mg2+. Tada Y; Yamaguchi J J Clin Microbiol; 1987 Nov; 25(11):2154-8. PubMed ID: 3320083 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antibacterial activities of FK037, a new parenteral cephalosporin. Nishino T; Otsuki M; Hatano K; Nishihara Y Chemotherapy; 1994; 40(3):167-82. PubMed ID: 8205935 [TBL] [Abstract][Full Text] [Related]
4. In vitro antibacterial activity of ceftizoxime against gram-negative strains. Debbia E; Soro O Chemioterapia; 1985 Apr; 4(2):166-9. PubMed ID: 3891115 [TBL] [Abstract][Full Text] [Related]
5. In vitro antibacterial activities of FK037: a new parenteral cephalosporin. Inoue K; Inoue E; Mitsuhashi S Chemotherapy; 1995; 41(4):257-66. PubMed ID: 7555206 [TBL] [Abstract][Full Text] [Related]
6. [Antimicrobial activities of cefetamet against clinical isolates from urinary tract infection]. Ishii Y; Suzuki Y; Ishihara R; Nakazawa A; Deguchi K Jpn J Antibiot; 1996 Dec; 49(12):1073-84. PubMed ID: 9032594 [TBL] [Abstract][Full Text] [Related]
7. Lactoferrin and transferrin damage of the gram-negative outer membrane is modulated by Ca2+ and Mg2+. Ellison RT; LaForce FM; Giehl TJ; Boose DS; Dunn BE J Gen Microbiol; 1990 Jul; 136(7):1437-46. PubMed ID: 2230724 [TBL] [Abstract][Full Text] [Related]
8. [Ceftizoxime: in vitro evaluation]. Fernández AJ; de Mier CA; Herran IL; Marcenac F Medicina (B Aires); 1989; 49(5):533-6. PubMed ID: 2487423 [TBL] [Abstract][Full Text] [Related]
9. Comparative activity of ceftizoxime against aminoglycoside-resistant aerobic gram-negative bacilli. Gómez-Lus R; Rubio MC; García C; Gómez-Lus ML; Alejandre MC Drugs Exp Clin Res; 1987; 13(3):155-9. PubMed ID: 3497792 [TBL] [Abstract][Full Text] [Related]
10. Post-antibiotic suppressive effect of ciprofloxacin against gram-positive and gram-negative bacteria. Chin NX; Neu HC Am J Med; 1987 Apr; 82(4A):58-62. PubMed ID: 3578330 [TBL] [Abstract][Full Text] [Related]
11. [Clinical laboratory approach for estimating effective administrative dose of cefuzonam. Evaluation of disc susceptibility test and its interpretation system]. Uete T; Matsuo K Jpn J Antibiot; 1988 Oct; 41(10):1407-17. PubMed ID: 3204654 [TBL] [Abstract][Full Text] [Related]
12. Comparative activity of ceftizoxime and four other cephalosporins against gram negative bacteria and their sensitivity to beta-lactamases. Esposito S; Galante D; Barba D; Pennucci C; Limauro D Microbiologica; 1985 Apr; 8(2):197-204. PubMed ID: 3874342 [TBL] [Abstract][Full Text] [Related]
13. Treatment of ciprofloxacin- and ceftizoxime-induced resistant gram-negative bacilli. Fasching CE; Gerding DN; Peterson LR Am J Med; 1987 Apr; 82(4A):80-6. PubMed ID: 3472465 [TBL] [Abstract][Full Text] [Related]
14. In-vitro comparison of ceftazidime and nine other antimicrobial agents against hospital strains of Gram-negative bacteria. Wilkinson LD; Gentry LO J Antimicrob Chemother; 1981 Sep; 8 Suppl B():53-6. PubMed ID: 19802969 [TBL] [Abstract][Full Text] [Related]
15. [Surveillance of resistance in the intensive care units using a cumulative antibiogram]. Yürüyen C; Daldaban Dinçer Ş; Yanılmaz Ö; Boz ES; Aksaray S Mikrobiyol Bul; 2018 Oct; 52(4):329-339. PubMed ID: 30522419 [TBL] [Abstract][Full Text] [Related]
16. [Comparative studies on activities of antimicrobial agents against causative organisms isolated from patients with urinary tract infections (2004). I. Susceptibility distribution]. Kumamoto Y; Tsukamoto T; Matsukawa M; Kunishima Y; Hirose T; Shigeta S; Yamaguti O; Ishibashi K; Suzutani T; Yoshida H; Imafuku Y; Murai M; Watanabe K; Kobayashi Y; Uchida H; Matsuda S; Sato S; Fujime M; Fujita K; Igari J; Oguri T; Yamaguchi K; Furuya N; Deguchi T; Ishihara S; Ooe H; Oka T; Kitamura M; Fukuhara Y; Kamidono S; Arakawa S; Kumon H; Monden K; Matsumoto T; Muratani T; Naito S; Egashira T; Konishi T; Kohno S; Hirakata Y; Kondo A; Matsuda J; Nakano M Jpn J Antibiot; 2006 Jun; 59(3):177-200. PubMed ID: 16913404 [TBL] [Abstract][Full Text] [Related]
17. [Post-marketing surveillance of antibacterial activities of cefozopran against various clinical isolates--II. Gram-negative bacteria]. Igari J; Oguri T; Hiramatsu N; Akiyama K; Koyama T Jpn J Antibiot; 2002 Feb; 55(1):22-60. PubMed ID: 11977920 [TBL] [Abstract][Full Text] [Related]